Practice
Open Access
Guillain–Barré syndrome
Ario Mirian, Michael W. Nicolle and Adrian Budhram
CMAJ March 15, 2021 193 (11) E378; DOI: https://doi.org/10.1503/cmaj.202710
Ario Mirian
Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ont.
MD MScMichael W. Nicolle
Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ont.
MD DPhilAdrian Budhram
Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ont.
MD![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Guillain–Barré syndrome
Ario Mirian, Michael W. Nicolle, Adrian Budhram
CMAJ Mar 2021, 193 (11) E378; DOI: 10.1503/cmaj.202710
Jump to section
- Article
- Guillain–Barré syndrome (GBS) is the most frequent cause of subacute neuromuscular weakness in North America
- Guillain–Barré syndrome usually presents with symmetric ascending weakness and hyporeflexia
- Cerebrospinal fluid (CSF) should be collected on presentation to exclude mimics before immunomodulatory therapy
- Intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) are effective treatments that hasten recovery
- Nearly one-third of patients will require mechanical ventilation, but the long-term prognosis is usually favourable
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.